High population immunity from prior infections and vaccinations, combined with consistent global surveillance showing only incremental Omicron sublineage changes, underpins the market's strong 95.5% implied probability against a new COVID variant of concern before 2027. The virus has settled into lower-virulence evolution patterns without the dramatic antigenic shifts seen earlier in the pandemic. Traders price in this stability because any candidate variant would need rapid, widespread impact to earn WHO designation, an outcome viewed as improbable in the remaining months of 2026. A realistic but low-probability scenario that could still shift odds involves an unexpected immune-evading mutation emerging and spreading quickly in under-monitored regions.